针对初级渐进性失言症的不同治疗干预措施的安全性和有效性:系统性审查
Abdulrahim Saleh Alrasheed1, Reem Ali Alshamrani2, Abdullah Ali Al Ameer3
1Department of Neurosurgery, College of Medicine, King Faisal University, AlAhsa 31982, Saudi Arabia.
Journal of clinical medicine
|May 14, 2025
概括
对于初级渐进性失言症 (PPA) 患者来说,各种疗法是有前途的,包括语音和语言干预以及大脑刺激技术. 然而,需要更多的研究来确定这种神经退行性疾病的最终治疗方案.
科学领域:
- 神经科学是一个神经科学.
- 语音和语言病理学 语言病理学
- 老年学是一门学科.
背景情况:
- 初级渐进性失言症 (PPA) 是一种影响语言的渐进性神经退行性疾病.
- 对PPA有效的治疗方法缺乏科学共识,需要对治疗干预措施的研究.
研究的目的:
- 系统地评估各种治疗干预措施的疗效和安全性,以治疗初级渐进性失言症.
- 确定潜在的治疗方法,以改善PPA患者的语言功能和整体治疗效果.
主要方法:
- 在Google学者,PubMed,科学网和科克兰图书馆的系统文献搜索.
- 包括57项涉及655名患有PPA的患者的研究.
- 主要结果:语言学习;次要结果:整体治疗效果.
主要成果:
- 几种疗法,包括无错学习,词汇检索级联 (LRC) 和重复性横磁性刺激 (rTMS),持续命名和词查找改进长达六个月.
- 重复的rTMS,视频实现的语盲脚本培训 (VISTA) 和结构化的口语阅读疗法增强了语音流性.
- 经治疗改善了听觉理解;经直流刺激 (tDCS) 结合治疗改善了重复,阅读精度和认知功能 (MMSE分数).
结论:
- 多种治疗干预措施表明,对患有PPA的个体有潜在的益处.
- 研究设计的异质性,样本规模小,缺乏标准化措施限制了最终的结论.
- 需要进一步进行严格的研究,以建立基于证据的PPA治疗方案.
相关概念视频
01:22Alzheimer's Disease: Treatment
132
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
132
01:26Psychosis: Goals of Pharmacotherapy
96
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
96